Table 2

Persistence data for osteoporosis medications by study

ReferenceMedicationsPopulation (mean age)Length of persistence (days)Patient persistence
6 months1 year2 years
Brankin et al31Alendronate, risedronate15 330 (71.7)233n/a55% (weekly regimen), 42.8% (daily regimen)n/a
Burden et al34Alendronate, etidronate, risedronate451 113 (75.6)n/an/a63.10%46.40%
Burden et al35Alendronate, etidronate, risedronate337 329 (75.7)n/an/a56%*, 66%†n/a
Carbonell-Abella et al22Alendronate, ibandronate, risedronate118 829 (66.9)n/an/a14.1% (alendronate daily), 56.5% (alendronate weekly), 35.8% (ibandronate monthly), 7.7% (risedronate daily),
31.2% (risedronate weekly), 40.0% (risedronate monthly)
n/a
Cheen et al36Alendronate, risedronate798 (68.5)n/an/a69%*n/a
Cheng et al23Alendronate1745 (68.1)n/an/a57.1%*41.8%*
Cotté et al39Alendronate, risedronate2990 (69.9)16945.7%*30.4%*n/a
Cramer et al40Alendronate, risedronate, ibandronate2741 (n/a)19644.6%* (daily), 58.1%* (weekly)31.7%* (daily), 44.2%* (weekly)n/a
Cramer et al41Alendronate, risedronate2741 (73)204n/a50%‡ (weekly), 38.6%‡ (daily)n/a
Curtis et al42Alendronate, risedronate1158 (53)n/a51.4%§ (alendronate)
46.8%§ (risedronate)
32.4%§(alendronate), 26.7%b (risedronate)9.5%§ (alendronate), 5.4%§ (risedronate)
Devine et al46Alendronate, ibandronate,
risedronate
22 363 (n/a)189.8* (weekly), 196.3* (monthly)n/an/an/a
Downey et al24Alendronate, risedronate10 566 (66.4)n/an/a21.3% (alendronate), 19.4% (risedronate)n/a
Dugard et al48Not stated254 (76.7)n/an/a74%¶59%¶
Ettinger et al49Alendronate, risedronate211 319 (n/a)n/an/a56.7%* (weekly), 39%* (daily)n/a
Gallagher et al51Alendronate, risedronate44 531 (n/a)n/an/a58.3%§n/a
Gold et al52Ibandronate, risedronate234 862 (n/a)144.3§ (risedronate),
100.1§ (ibandronate)
29%§ (ibandronate)
56%§(risedronate)
n/an/a
Gold et al53Alendronate4769 (n/a)261*38%* (daily), 49%* (weekly)26%* (daily), 36%* (weekly)16%* (daily), 24%* (weekly)
Gold et al54Ibandronate, risedronate263 383 (66.21)151.54§ (bandronate)
250.04§ (risedronate)
n/a18.4%§ (ibandronate), 40%§ (risedronate)n/a
Hadji et al55Alendronate, clodronate,
etidronate, risedronate
4147 (n/a)145.5*n/a27.9%*12.9%*
Hadji et al25Alendronate, clodronate,
etidronate, risedronate
19 752 (n/a)n/an/a26%*20.1%*
Hadji et al56Clodronate, ibandronate,
pamidronate, zoledronate
280 (63.2)n/an/a45.6%§n/a
Hansen et al27Alendronate, other oral bisphosphonates100 556 (70.4)1463** (alendronate)
532.9** (clodronate)
963.6** (etidronate)
1408.9** (ibandronate)
1018** (risedronate)
n/an/an/a
Hansen et al57Alendronate198 (71)n/an/an/a28%
Hawley et al58Not stated21 385 (n/a)n/a45.65%n/an/a
Hoer et al59Alendronate, etidronate,
risedronate
4451 (n/a)n/a71.3%*47.3%*14.5%*
Ideguchi et al60Alendronate, etidronate,
risedronate
1307 (61.3)n/an/a74.8%§60.6%§
Iolascon et al28Alendronate, risedronate,
ibandronate
18 515 (68.9)n/an/a12.6%* (alendronate), 15.8%* (risedronate), 21.6%* (ibandronate)n/a
Jones et al61Alendronate, risedronate,62 897 (n/a)n/a72%* (alendronate weekly)
71.2%* (risedronate weekly)
56.3%* (alendronate weekly), 54.4%* (risedronate weekly)n/a
Kamatari et al62Alendronate, risedronate1274 (74)n/an/a42.5% * (alendronate),44.6% * (risedronate)n/a
Kertes et al63Alendronate, risedronate4448 (n/a)216*n/a46%*n/a
Kishimoto and Machara64Not stated12 230 (59.8)n/an/a33.2%* (daily regimen)13.0%* (daily), 32.7%* (weekly), 50.4%* (weekly regimen)
Lakatos et al65Alendronate, risedronate, ibandronate296 300 (68.3)n/a50%†† (alendronate), 50% †† (ibandronate),
55% †† (risedronate)
35% †† (alendronate), 30% ††(ibandronate), 42% ††(risedronate)20%††† (alendronate), 16% ††† (ibandronate),
22% ††† (risedronate)
Landfeldt et al66Alendronate, risedronate56 586 (71)n/an/a55%†† (alendronate), 54% †† (risedronate)38%†† (alendronate), 38%†† (risedronate)
LeBlanc et al67Not stated14 674 (71)n/an/a58%¶¶23%‡‡
Li et al68Alendronate, etidronate, risedronate, ibandronate66 116 (71.4)n/a27%* (alendronate daily), 52.8%* (alendronate weekly),
56.8%* (Ibandronate monthly), 37.8%* (risedronate daily),
53.1%* (risedronate weekly)
17.6%* (alendronate daily), 41.3%* (alendronate weekly), 6.5%* (ibandronate monthly),
26.4%* (risedronate daily), 41.1%* (risedronate weekly)
n/a
Lo et al70Alendronate13 455 (68.8)378†40%†50%†n/a
McCombs et al72Alendronate, etidronate,
risedronate
3720 (69.1)170n/an/an/a
Modi et al73Alendronate, etidronate,
risedronate
75 593 (64.4)115.6*39.30%*n/an/a
Netelenbos et al76Alendronate, etidronate, ibandronate,
risedronate
105 506 (69.2)n/a43.10%§§n/an/a
Papaioannou et al78Alendronate, etidronate1673 (66.8)n/an/a77.6% (alendronate), 90.3% (etidronate)70.1% (alendronate), 80.5% (etidronate)
Penning-van Beest et al80Alendronate, risedronate2124 (71.6)n/an/a42.9%*n/a
Rabenda et al83Alendronate54 807 (n/a)n/a58%¶¶40%¶¶n/a
Richards et al86Alendronate, risedronate573 (68.7)1176§n/an/a
Rietbrock et al87Alendronate, risedronate44 531 (71)n/an/a58.30%n/a
Roerholt et al88Alendronate, etidronate, ibandronate6210 (74.7)474 (alendronate 10 mg),
1350.5 (alendronate 70 mg),
803 (etidronate)
n/an/an/a
Roughead et al89Not stated42 885 (80.8)n/an/an/a
Sampalis et al90Alendronate, ibandronate ,
Risedronate
636 114 (72)n/a41.0%*41.0%*26.6%*
Sheehy et al92Alendronate32 804 (n/a)n/a79% ***65%***n/a***
Siris et al93Alendronate, risedronate35 357 (65.3)n/an/an/a20%*
Soong et al95Alendronate32 604 (72.4)n/a48.03%*17.6%*n/a
Ström96Alendronate, risedronate36 433 (70.2)n/an/a51.67%††n/a
Sunyecz et al97Alendronate, risedronate32 944 (64.3)n/an/an/a21%*(3 years)
Van Boven et al99Alendronate, etidronate,
Ibandronate, risedronate
8610 (67.5)n/an/a48.9%*40%*(3 years)
Van den Boogaard et al100Alendronate, etidronate,
risedronate
14 760 (n/a)n/an/a43.60%27.40%
Weiss et al102Alendronate, ibandronate,
risedronate
165 955 (67.1)109*n/an/an/a
Weycker et al103Alendronate, risedronate18 822 (62.2)n/a45.5%§(daily),47.3% § (weekly)19.2%§ (daily)3.7%§ (daily), 3.6%§(weekly)
Yeaw et al105Alendronate, ibandronate,
risedronate, zoledronate, etidronate, pamidronate
10 268 (56.9)n/a56%*41%†n/a
Ziller et al108Alendronate, etidronate, risedronate268 568 (63.3)239.8 hour (alendronate 70 mg), 218.7§ (alendronate +vitamin D),
246.4§ (etidronate), 256.4§ (ibandronate 150mg),
190.9§ (residronate)
n/a44.8% hour (alendronate 70 mg), 37.8%h (alendronate +vitamin D),
43.4%h (etidronate), 50.8%h (ibandronate), 30.3%h (residronate)
n/a
  • *Persistence with no refill gaps ≥ 30 days.

  • †Persistence with no refill gabs > 60 days.

  • ‡Patient persistence defined as length of time before a refill gap > 30 days.

  • §Persistence with no refill gaps ≥ 90 days.

  • ¶Persistence was defined as complete cessation or a gap > 12 months.

  • ** Persistence with as no refill gaps > 56 days/8 weeks, n/a means not reported.

  • ††Persistence with no refill gaps > 8 weeks.

  • ‡‡Persistence was defined as the length of time until a refill gap > 3 months.

  • §§Persistence with no refill gaps > 6 months, n/a means not reported.

  • ¶¶Persistence was defined as length of time without a refill gap > 5 weeks.

  • ***Persistence was defined as length of time until refill gap exceeding 1.5 x prescription length, n/a means not reported.